TScan Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · AccumulatedOther · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Non-voting Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Shares · Amount · Capital · Loss · Deficit · Equity | |||||||||
| Balances at January 1, 2025 | 52,314,039 | $5 | 4,276,588 | $1 | $616,009 | $51 | $(375,096) | $240,970 | |
| Stock-based compensation expense | - | - | - | - | 3,414 | - | - | 3,414 | |
| Net loss | - | - | - | - | - | - | (34,127) | (34,127) | |
| Unrealized loss on available-for-sale securities | - | - | - | - | - | (55) | - | (55) | |
| Balances at March 31, 2025 | 52,314,039 | $5 | 4,276,588 | $1 | $619,423 | $(4) | $(409,223) | $210,202 | |
| Balances at January 1, 2026 | 52,625,035 | $5 | 4,276,588 | $1 | $627,979 | $ | - | $(504,862) | $123,123 |
| Issuance of common stock upon exercise of pre-funded warrants | 3,199,687 | 1 | - | - | (1) | - | - | - | |
| Stock-based compensation expense | - | - | - | - | 2,465 | - | - | 2,465 | |
| Net loss | - | - | - | - | - | - | (28,666) | (28,666) | |
| Balances at March 31, 2026 | 55,824,722 | $6 | 4,276,588 | $1 | $630,443 | $ | - | $(533,528) | $96,922 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.